It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with multiple endocrine neoplasia syndrome type 2.
Semaglutide
Albiglutide
Teduglutide
Dulaglutide
Liraglutide
Linagliptin
Exenatide
Saxagliptin